Evaxion A/S (NASDAQ:EVAX) Research Coverage Started at JonesTrading

JonesTrading started coverage on shares of Evaxion A/S (NASDAQ:EVAX) in a research report report published on Tuesday morning,Benzinga reports. The firm issued a buy rating and a $10.00 price target on the stock.

A number of other research analysts also recently weighed in on EVAX. Lake Street Capital lowered their price target on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Monday. Maxim Group assumed coverage on Evaxion A/S in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a report on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.00.

Evaxion A/S Stock Up 8.0%

EVAX stock opened at $4.18 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.85 and a quick ratio of 5.85. The firm has a market capitalization of $34.86 million, a P/E ratio of -3.17 and a beta of 0.28. Evaxion A/S has a 52-week low of $1.20 and a 52-week high of $12.15. The company’s 50 day simple moving average is $3.81 and its 200-day simple moving average is $4.62.

Evaxion A/S (NASDAQ:EVAX) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.30 EPS for the quarter. As a group, equities research analysts anticipate that Evaxion A/S will post -0.15 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Wesbanco Bank Inc. acquired a new stake in shares of Evaxion A/S in the 4th quarter valued at $48,000. Northwestern Mutual Wealth Management Co. bought a new stake in Evaxion A/S in the fourth quarter worth $38,000. Finally, SmartHarvest Portfolios LLC acquired a new position in Evaxion A/S during the fourth quarter worth $72,000. Institutional investors own 11.04% of the company’s stock.

Evaxion A/S News Roundup

Here are the key news stories impacting Evaxion A/S this week:

• Positive Sentiment: JonesTrading initiated coverage with a Buy recommendation, providing fresh institutional attention that likely helped the stock’s upward move. JonesTrading Begins Coverage on Evaxion
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and maintains a $16 price target, signaling continued analyst conviction in Evaxion’s long‑term upside despite near‑term volatility. HC Wainwright Reaffirms Buy Rating
• Positive Sentiment: Management’s Q4 2025 earnings call emphasized strategic partnerships and a strong cash position, which supports funding runway and de‑risking of development programs. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analysts’ consensus remains a “moderate buy,” reflecting mixed views — institutional support exists but estimates vary materially across timelines. Moderate Buy Consensus
• Negative Sentiment: HC Wainwright trimmed several multi‑year EPS forecasts (FY2027–FY2030), lowering some prior estimates — this reduces near‑term earnings visibility and raises model risk. HC Wainwright Lowers Estimates
• Negative Sentiment: Lake Street Capital lowered its price target to $9.00, a nearer‑term valuation cap that could pressure sentiment if other brokers follow. Lake Street Lowers PT

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.